|
Sat, 04/05/2025 - 17:34 |
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit |
|
Thu, 03/27/2025 - 18:04 |
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Thu, 03/06/2025 - 20:34 |
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference |
|
Tue, 02/04/2025 - 18:00 |
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
|
Wed, 07/10/2024 - 23:16 |
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences |
|
Tue, 06/04/2024 - 17:45 |
Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes |
|
Fri, 05/17/2024 - 00:46 |
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer |
|
Mon, 12/12/2022 - 13:25 |
Regulus Therapeutics Announces Resignation of Board Member |
|
Mon, 11/28/2022 - 19:35 |
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations |
|
Wed, 11/02/2022 - 16:56 |
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Thu, 10/27/2022 - 09:21 |
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 |
|
Thu, 09/01/2022 - 19:03 |
Regulus Therapeutics to Participate in Upcoming Investor Conferences |
|
Tue, 06/21/2022 - 04:52 |
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Mon, 06/13/2022 - 07:35 |
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Thu, 06/02/2022 - 00:31 |
Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK |
|
Tue, 05/17/2022 - 19:01 |
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference |
|
Wed, 05/11/2022 - 00:58 |
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Wed, 03/23/2022 - 22:27 |
Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital |
|
Thu, 02/24/2022 - 19:29 |
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome |
|
Thu, 02/10/2022 - 18:42 |
Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference |
|
Mon, 10/11/2021 - 19:42 |
Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease |
|
Thu, 09/30/2021 - 09:20 |
Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science |
|
Wed, 09/08/2021 - 21:50 |
Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference |
|
Fri, 06/25/2021 - 17:36 |
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 |
|
Mon, 06/21/2021 - 00:10 |
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 |
|
Thu, 05/20/2021 - 22:52 |
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program |
|
Fri, 05/14/2021 - 00:02 |
Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit |
|
Sun, 05/02/2021 - 22:43 |
Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Wed, 04/14/2021 - 22:12 |
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Tue, 04/06/2021 - 22:47 |
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference |
|
Fri, 03/05/2021 - 16:28 |
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference |
|
Wed, 02/10/2021 - 15:56 |
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Wed, 01/27/2021 - 17:22 |
Regulus Announces Addition to Board of Directors |
|
Tue, 01/05/2021 - 17:08 |
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference |
|
Tue, 12/08/2020 - 16:26 |
Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity |
|
Mon, 11/02/2020 - 18:34 |
Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi |
|
Thu, 10/15/2020 - 16:15 |
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Wed, 08/05/2020 - 21:19 |
Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference |
|
Tue, 07/28/2020 - 21:50 |
Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Tue, 07/21/2020 - 22:36 |
Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
|
Thu, 02/13/2020 - 01:09 |
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD |
|
Mon, 12/16/2019 - 03:39 |
Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326 |
|
Mon, 11/18/2019 - 03:54 |
Regulus Therapeutics to Present at the Stifel Healthcare Conference |
|
Tue, 10/15/2019 - 20:52 |
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting |
|
Thu, 09/12/2019 - 08:44 |
Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD |
|
Tue, 07/30/2019 - 05:06 |
Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer |
|
Tue, 07/23/2019 - 18:59 |
Regulus Therapeutics Announces RGLS4326 Program Update |
|
Tue, 06/11/2019 - 04:57 |
Regulus Announces New Additions to Board of Directors |
|
Tue, 05/07/2019 - 06:24 |
Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity |
|
Mon, 05/06/2019 - 05:58 |
Regulus Therapeutics Announces Private Placement of Equity |
|
Mon, 05/06/2019 - 05:32 |
Regulus Therapeutics Announces Restructuring of Term Loan |
|
Mon, 04/08/2019 - 06:01 |
Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress 2019 |
|
Fri, 03/15/2019 - 04:37 |
Regulus Announces Transition of Research Leadership |
|
Sun, 01/06/2019 - 19:11 |
Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme |
|
Thu, 01/03/2019 - 22:07 |
Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study |
|
Sun, 11/18/2018 - 20:16 |
Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme |
|
Mon, 11/05/2018 - 20:35 |
Regulus Announces Successful Restructuring of Sanofi Collaboration |
|
Wed, 10/24/2018 - 20:21 |
Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018 |
|
Sun, 10/21/2018 - 20:19 |
Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018 |
|
Wed, 10/03/2018 - 19:49 |
Regulus Therapeutics Announces Reverse Stock Split |
